DonaldGregoryTherasseMD

PubMed

• 1 citations
  Considerations for applying bioethics norms to a biopharmaceutical industry setting.
  Luann E. Van Campen, Tatjana Poplazarova, Donald G. Therasse, Michael Turik> ;BMC Medical Ethics. 2021 Mar 25
• 3 citations
  Development, implementation and critique of a bioethics framework for pharmaceutical sponsors of human biomedical research
  Luann E. Van Campen, Donald G. Therasse, Mitchell Klopfenstein, Robert J. Levine> ;Current Medical Research and Opinion. 2015 Oct 15
• 3 citations
  Eli Lilly and Company’s bioethics framework for human biomedical research
  Luann E. Van Campen, Donald G. Therasse, Mitchell Klopfenstein, Robert J. Levine> ;Current Medical Research and Opinion. 2015 Oct 13
• 5 citations
  A Pharmaceutical Bioethics Consultation Service: Six-Year Descriptive Characteristics and Results of a Feedback Survey.
  Luann E. Van Campen, Albert J. Allen, Susan B. Watson, Donald G. Therasse> ;AJOB Empirical Bioethics. 2015 Apr 3
• Cefaclor and Cefuroxime Axetil in the Treatment of Otitis Media—An Alternative View
  David A. Preston, Donald Therasse, Michael L. Zeckel> ;The Journal of Infectious Diseases. 1998 Nov 1
• 5 citations
  Effects of renal dysfunction on the pharmacokinetics of loracarbef
  Donald G Therasse, Diane S Farlow, Robert L Davidson, Leonard J Quadracci, Barbara L. Hatcher, Benito J. Cerimele, Karl A. DeSante> ;Clinical Pharmacology and Therapeutics. 1993 Sep 1
• 14 citations
  The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections.
  Donald G. Therasse> ;The American Journal of Medicine. 1992 Jun 22
• The epidemiology of pseudallescheriasis complicating transplantation: Nosocomial and community-acquired infection.
  Patterson, T. F.,Andriole, V. T.,Zervos, M. J.,Therasse, D.,Kauffman, C. A.> ;Mycoses. 1990 Jun 01
• 4 citations
  Compliance with a restricted antimicrobial agent policy in a university hospital.
  Burgunda W. Volger, Mary B. Ross, Helen R. Brunetti, David D. Baumgartner, Donald G. Therasse> ;American Journal of Hospital Pharmacy. 1988 Jul 1
• Comprehensive safety profile of cefaclor AF in respiratory, urinary tract and skin infections.
  Stotka, J. L., Senetar, J. E., Therasse, D. G., Dere, W. H.> ;Postgrad Med J. 1992
• Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis.
  Sydnor, T. A., Scheld, W. M., Gwaltney, J., Nielsen, R. W., Huck, W., Therasse, D. G.> ;Ear Nose Throat J. 1992 May
• Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in adults.
  McCarty, J., Hernon, Y., Linn, L., Therasse, D. G., Molina, A., Bleile, N.> ;Clin Ther. 1992 Jan 01
• Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis.
  Dere, W. H., Farlow, D., Therasse, D. G., Ruoff, G. E.> ;Clin Ther. 1992 Jan 01
• Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
  Dere, W. H., Farlow, D., Therasse, D. G., Jacobson, K. D., Guerra, F. J.> ;Clin Ther. 1992 Mar 01
• Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
  Zeckel, M. L., Jacobson, K. D., Guerra, F. J., Therasse, D. G., Farlow, D.> ;Clin Ther. 1992 Mar 01
• The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection.
  Patterson, T. F., Andriole, V. T., Zervos, M. J., Therasse, D., Kauffman, C. A.> ;Mycoses. 1990 Jun
• Join now to see all

Journal Articles

• CROs: Selecting and managing contract regulatory development resources  
  Franson T, Therasse D, 1/1/2015
• Development, implementation, and critique of a bioethics framework for pharmaceutical sponsors of human biomedical research  
  Van Campen LE, Therasse DG, Klopfenstein MA, Levine RL, Curr Medl Res Opin, 1/1/2015
• Eli Lilly and Company's bioethics framework for human biomedical research  
  Van Campen LE, Therasse DG, Klopfenstein MA, Levine RL, Curr Med Res and Opin, 1/1/2015
• Cefaclor and cefuroxime axetil in the treatment of otitis media - an alternative view  
  Preston D, Therasse D, Zeckel ML, J Inf Dis, 1/1/1998
• Antibacterial activity of loracarbef  
  Zeckel ML, Therasse DG, Drugs of Today, 1/1/1995
• Pharmacokinetic profile of loracarbef  
  Zeckel ML, Therasse DG, Drugs of Today, 1/1/1995
• Effects of renal dysfunction on the pharmacokinetics of loracarbef  
  Therasse DG, Farlow DS, Davidson RL, Quadracci LJ, Hatcher BL, Cerimele BJ, DeSante KA, Clin Pharm Ther, 1/1/1993
• Loracarbef: Safety and tolerance  
  Dere WH, Therasse DG, J Chemotherapy, 1/1/1993
• Loracarbef (LY163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis  
  Sydnor TA, Scheld WM, Gwaltney J, Nielson RW, Huck W, Therasse DG, Ear Nose Throat J, 1/1/1992
• Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchits  
  Dere WH, Farlow D, Therasse DG, Jacobson KD, Guerra FJ, Clin Ther, 1/1/1992
• Comprehensive safety profile of cefaclor AF in respiratory, urinary tract, and skin infections  
  Stotka JL, Senetar JE, Therasse DG, Dere WH, Postgrad Med J, 1/1/1992
• Compliance with a restricted antimicrobial agent policy in a university hospital  
  Vogler B, Ross M, Brunetti H, Baumgartner D, Therasse D, J Hosp Pharm, 1/1/1988
• Join now to see all

Abstracts/Posters

• The role of bioethics in the pharmaceutical industry: Informal review of 5-year trends and one company's systematic approach.
  Van Campen LE, Therasse DG, Encore Presentation - Public Responsibility in Medicine and Research - Advancing Ethical Research Conference, 1/1/2015
• The role of bioethics in the pharmaceutical industry: Informal review of 5-year trends and one company's systematic approach.
  Van Campen LE, Therasse DG, Drug Information Association 50th Annual Meeting, 1/1/2014
• Bioethics capacity building in a corporate setting: One pharmaceutical company's experience.
  Van Campen LE, Therasse DG, Beauchamp TL, Levine RJ, American Society for Bioethics and Humanities 15th Annual Meeting, 1/1/2013
• Development of a bioethics framework for pharmaceutical human biomedical research.
  Van Campen LE, Klopfenstein M, Therasse DG, American Society for Bioethics and Humanities 14th Annual Meeting, 1/1/2012
• A tiered approach for pharmaceutical research and development bioethics consultations.
  Van Campen LE, Klopfenstein ML, Therasse, DG, American Society for Bioethics and Humanities 12th Annual Meeting Program, 1/1/2010
• Environmental role in the epidemiology of Clostridium difficile.
  Bacon A, Devlin HR, Therasse D, Fekety R, 95th Annual Meeting of the American Society of Microbiology, 1/1/1995
• Predictive value of quantitative sinus aspirate culture on clinical response in acute maxillary sinusitis: A review of loracarbef sinusitis trials.
  Zeckel M, Therasse D, Masica D, Nord CE, 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy, 1/1/1993
• The pharmacokinetic profile of loracarbef.
  Zeckel M, Therasse, D, 5th European Congress of Clinical Microbiology and Infectious Diseases, 1/1/1991
• Daptomycin versus conventional therapy in the treatment of endocarditis and bacteremia.
  Lee BL, Chambers HF, Novak RM, Rodvold KA, Kaatz G, Rybak M, McCloskey R, Zeckel M, Therasse, D, 31st Interscience Conference of Antimicrobial Agents and Chemotherapy, 1/1/1991
• Randomized trial of LY163892, a new oral carbacephem antibiotic, vs. amoxicillin/clavulanate potassium in the treatment of bronchitis.
  McCarty J, Froehlich H, Renteria A, Linn L, Farlow D, Therasse D, Fourth European Congress of Clinical Microbiology, 1/1/1989
• The use of daptomycin, a lipopeptide antibiotic, in the treatment of gram-positive infections in man.
  Sexton D, Brown R, McCloskey R, Dowell A, Therasse D, 28th Interscience Conference of Antimicrobial Agents and Chemotherapy, 1/1/1988
• Prevention of Clostridium difficile colitis in hamsters with teicoplanin.
  Baumgartner D, Therasse D., Weber D, Perry S, Fekety R, 27th Interscience Conference of Antimicrobial Agents and Chemotherapy, 1/1/1987
• Prevention of Clostridium difficile colitis in hamsters with LY146032.
  Baumgartner D, Therasse D, Weber D, Perry S, Fekety R, 27th Interscience Conference of Antimicrobial Agents and Chemotherapy, 1/1/1987
• Join now to see all